Building the biological data layer for AI
Alphabiome is the AI layer for drug development. We read the raw bacterial, viral, and host DNA that has no reference map, computing over signal others can’t, to reveal which therapies work, in which patients and why.
21/11/2025
New peer-reviewed publication: Alphabiome.ai AI Model Proven in Large-Scale Dairy Study
Our AI model, predicting the efficacy of an allicin-based essential oil for methane reduction, was peer-reviewed in Frontiers. The study validated our approach in 339 dairy cows on ten commercial farms.
25/11/2025
Dr. Yaniv Altshuler Presents Alphabiome’s Microbiome-AI Breakthroughs at AIDDD Summit
At the recent AIDDD Summit, our CEO highlighted Alphabiome’s cutting-edge microbiome-AI technology and its growing impact on precision treatment prediction.
25/09/2025
Validation of Alphabiome’s AI model for predicting microbiome-driven outcomes
A peer-reviewed study confirms the accuracy of Alphabiome’s AI model, validated in a controlled livestock trial assessing the methane-reducing effect of a nutritional additive.
06/05/2025
Alphabiome Unveils Revolutionary AI Technology for Microbiome Decoding
Yahoo Finance- Using proprietary algorithms and advanced modeling, Alphabiome deciphers hidden microbial DNA to accurately predict individual drug response — setting a new standard in personalized medicine.
06/05/2025
AI That Predicts Drug Response Powered by the Microbiome
Health Technolog Net- Alphabiome’s proprietary platform analyzes microbial DNA beyond reference genomes, delivering unmatched accuracy in forecasting therapeutic outcomes.
07/05/2025
Alphabiome Raises $8M to Scale Microbiome AI
Finsmes.com- Alphabiome secures seed funding to expand R&D and advance its proprietary platform for predicting drug response with greater precision.
Discover Alphabiome
Learn more about how Alphabiome’s groundbreaking technology is opening new frontiers in precision medicine.
What We Do
Our Partners
